PCI can achieve similar resultstoCABG, but many
RCTsw hich have demonstrated this have tended to exclude most patients who stand to gain most from CABG (see above) 3. Immediate mortality from CABG is greater than from PCI, although thereisevidence that risk-adjusted mortalityofboth procedures is falling. 4. PCI is much, much less invasive than CABG and offers amoreattractive"quick fix" to both patients and their doctors. 5. Technology is changingr apidly,s ot hat any trial looking at long-term survival is likely to be out of date by the time results areavailable (Fig. 2) .
Because cardiologists tend to be the gatekeepers, the first-line treatment for coronary disease has largely becomePCI, with CABG being considered only if the patient is deemed unsuitable for PCI or if repeated PCI fails. As PCI has become entrenched as the default therapy,thereissome concern that patientsare not being given the option of alternative therapy, such as medical treatment or CABG, so that theprinciple of fullyi nformed consent is not being rigorously applied. The basic rules in medical practice have not changed�� there are only two reasons to offer treatment:
1. to improve symptoms, 2. to improve prognosis.
The indication for treatment on symptomatic grounds is simple: less invasive first! For angina, try drugs first,t hen PCI if drugs fail, then CABG. The indicationfor treatment on prognostic grounds is moredifficult. To date, thereisnoevidence that the superiority of CABG in prognostically important coronary disease has been seriously challenged by PCI. Thereforethe question that should be posed to the patient is the following: arey ou prepared to accept the risk of CABG in order to gain the prognostic benefit?I f the answerisyes, we should offer CABG.
In 1994 Yusuf et al published am eta-analysis of seven RCTs comparingCABG to medical therapy(1). At that time the mortality for CABG was around 4%, but even then, the conclusion wasthat CABG is better than medical therapy for patients with moree xten-
INTRoDUCTIoN
The 1970s saw massive expansion in coronary artery bypass grafting (CABG), which reigned supreme as the preferred and most effective treatment for symptomatic and asymptomatic ischaemic heart disease, offering excellent relief from symptomsa sw ell as real prognostic benefits in several patient subgroups until the advent of percutaneous coronary intervention (PCI). The wide availability of PCI and the reduction in restenosis rates reported first for bare metal stents(BMS) and drug-eluting stents(DES) has radically modified the treatment strategies in patients with ischaemic heart disease, to the extent that percutaneous therapies have been hailed as proclaiming that CABG and perhaps even cardiac surgery in general now face imminent extinction.
BACKGRoUND
Despite the large numbers of studies, including randomised controlled trials(RCTs) which have tackled the thorny issue of myocardial revascularisation modalities, it remains difficult to discern anyclear superiority of CABG or PCI, and this becomes even more difficult in thesetting of aspecific subgroup, like that of heart failure (Fig. 1 ).
Let us first approach the questiono fP CI versus CABG in general. Without carryingo ut af ull metaanalysis of the various trials, the following can be said to be adistillate of our knowledge so far:
1. CABG achieves better symptom relief than medical therapya nd has better prognostic benefits in left main stem and multivessel disease. The differencei se nhanced in patientsw ith impaired left ventricular (LV) function. sive disease.The studyshowed asignificant survival advantage for CABG in patients with angina CCS 3-4 (7.3 months) and with LV dysfunction (10.6 months).I nt he UK, current overall hospital mortality of CABG is around 2%, so the survival benefits now are, if anything, likely to be greater.A lthough some RCTshave not shown asurvival advantage for CABGo ver PCI (2), this has been taken to show equivalence. This is arisky conclusion for the reasons statedp reviously: most early RCTsh ave tended to exclude the very patients whose coronary disease has asignificant impact on prognosis. The ongoing Syntax trialisprobably the first largescale trial of CABG versus PCI in all-comers, including patients with prognostically important disease. Until its results become available, CABG should remain the mainstay of treatment for patients with multivessel or left main disease, and especially so in patients with left ventricular dysfunction.o ther trials have included large cohorts of single and double-vessel diseasew ith normal LV function, even though these patients have consistently been shown to have no prognostic benefit from CABG when compared to PCI (3), or indeed to medical therapy.
REVASCULARISATIoN IN HEARTF AILURE
The recently published "revascularisation in ischaemic heart failure"t rial (REHEAT) is ap rospective (non-randomised) case-controlled study comparing early and late results of CABG and PCI in patients with ischaemic cardiomyopathy,with particular emphasiso nc hanges in LV functiona st he outcome measure(4). The trial recruited 141 patients with LV ejection fraction (EF) <40%. The authors concluded that both PCI and CABG areassociated with comparable improvements in LVEF in patients with ischaemic cardiomyopathy (mean increase 6.0 ±7.2% for PCI, 4.4 ±9.0% in CABG, p=0.12). Therewas abetter 1-year survival with PCI, but al ower incidence of repeat revascularisation with CABG. As one would expect such patients to have poor LV function and thereforem ost likely to benefit prognostically from CABG,these findingsappear to be contrary to expectations and shouldbecritically examined.
The poorer 1-year survival with CABG was based on 4deaths <30days reported in the surgery group, however 2o ft hese deaths occurred in patients who wereawaiting surgery.T ime to intervention was not stated in either group, although it was reported that patients in the PCI group spent less time in hospital. The patients were not randomised and were allocated PCI or surgery on the basis of doctor or patient preference so selection bias is likely and, although patients werematched for the number of diseased vessels, the severityo fd isease was not mentioned. It seems likelyt hat patients referred for surgery may have had disease unsuitable for PCI and therefore perhaps mores evere. In the year after treatment, CABG patients had less angina than the PCI group, and the number of adverse events (unstable angina, pulmonary oedema, repeat revascularisation) was significantly higherinthe PCI group from 30 days to 12 months.
One important finding of the REHEATtrial is that there appears to be some improvement in LV function after revascularisation, but this is at best modest. The main prognostic advantage of revascularisation in such patients may not be due to any dramatici mprovement in LV function, but to the possible halt or slowing down of futuredeterioration. In this context, the use of PCI in such patients shouldprobably continue to followoverall guidelines of best practice. In other words, PCI should be considered for symptomatic single or double vessel disease without left main stem stenosis. Patients without angina who have ischaemic LV dysfunction should probablyonly be offered revascularisation (PCI or CABG as appropriate) if thereisstrong evidenceofreversibleischaemia.Angina itself provides direct evidenceofreversible ischaemia, so this is not an issue in patients with this symptom. The debate over DES versus BMS has intensified recently as the American Food and Drug Administration (FDA) reviewed the evidence for both. As recently as 2005, studies werep ublished expounding the superiority of DES over BMS in left main stem lesions (5). However,a ccording to FDA guidelines, approved indications for DES arel imited to newly diagnosed coronary lesions, less than 28-30 mm long, in clinically stablepatients without additional serious medical conditions (6). It is estimated that 60% of use of DES is off-label, even though recentt rials have demonstrated off-label use is associated with increased risks of both early and late stent thrombosis, and increased rates of death and myocardial infarction.
Absoluterisk of in-stent thrombosis for approved indicationsi sq uoteda s2 %t hroughoutt he first 3 years of implantation.H owever,i ti su nknown whether cases of in-stent thrombosis will continue to accrue over time. The risk of thrombosis in patients who have DES for non-approved indications has not been specified, except to say that it is increased. The The FDA also believe that large RCTsare required to definet he best treatment strategiesf or lesionsi np atients with common, complex conditions like multivessel coronary disease, diabetes and acute myocardial infarction. We argue that all the sound evidence to date (as already discussed) points to the superiority of CABG for all these types of patients, especially in multivessel disease.
Spaulding et al concluded that BMSare associated with lower mortality than sirolimus-eluting stents in diabetic patients (7) and it is widely recognised that CABG is superior in this group of patients (8). Studies have not demonstrated any long-term difference in myocardial infarction or mortality rates in patients treated with DES compared to BMS, although neither have they proven any advantage in either of these outcomes by using DES (7, 9, 10) . In fact, al arge Swedish study concluded that DES werea ssociated with an increased death rate as compared with BMS, although this finding may be related to early discontinuationo fc lopidogrel (11) . Although therew as a sustained reduction in the need for re-intervention after the placement of sirolimus-eluting stents,t he risk of in-stentthrombosis was at least as greatas that seen with BMS (10).
CoNCLUSIoN
In patients with impaired LV function due to ischaemia, both PCI and CABG provide limited improve-ment in LV function, reduce symptoms of anginaand improve exercise tolerance. However,D ES aren ot licensed for patients with multivessel disease and all the evidence reviewed herepoints to the superiority of outcome with CABG in this group of patients ( Fig. 3) .
Given the recent concerns about late in-stent thrombosis rates, it will be interesting to seethe longtermfollow-up results of these patient cohorts. In the meantime, the primaryi ndications for CABG on prognostic grounds have not changed: CABG is still the treatment of choice in patients with ischaemic heart failurew ho fulfil the criteria for ap rognostic benefit: left main stem disease and triple vessel disease. Indeed, it can be argued that, until therei s evidence to the contrary,i schaemic heart failure strengthens the indication for CABG even further. 
